Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Novo Nordisk A/S
Novo Nordisk A/S News
Novo Nordisk A/S Quantitative Score
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S Earnings & Revenue
Novo Nordisk A/S Financials
Table Compare
Compare NVO metrics with: | |||
|---|---|---|---|
Earnings & Growth | NVO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NVO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NVO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NVO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Novo Nordisk A/S Income
Novo Nordisk A/S Balance Sheet
Novo Nordisk A/S Cash Flow
Novo Nordisk A/S Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Novo Nordisk A/S Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 3.1139 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2025-04-08 | 0.78742 | Quarterly |
| 2024-08-26 | 0.51264 | Quarterly |
| 2024-04-02 | 0.92985 | Quarterly |
| 2023-08-29 | 0.884 | Quarterly |
| 2023-04-04 | 1.189 | Quarterly |
Novo Nordisk A/S Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Novo Nordisk A/S Executives
| Name | Role |
|---|---|
| Mr. Lars Fruergaard Jorgensen | President, Chief Executive Officer & Member of Management Board |
| Mr. Henrik Ehlers Wulff | Executive Vice President of Product Supply, Quality & IT and Member of the Management Board |
| Mr. Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board |
| Ms. Camilla Sylvest | Executive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management Board |
| Dr. Martin Holst Lange | Executive Vice President of Development & Member of the Management Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Lars Fruergaard Jorgensen | President, Chief Executive Officer & Member of Management Board | Male | 1966 | 4.73M |
| Mr. Henrik Ehlers Wulff | Executive Vice President of Product Supply, Quality & IT and Member of the Management Board | Male | 1970 | 1.89M |
| Mr. Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board | Male | 1971 | 1.87M |
| Ms. Camilla Sylvest | Executive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management Board | Female | 1972 | 1.84M |
| Dr. Martin Holst Lange | Executive Vice President of Development & Member of the Management Board | 1970 | 1.79M |